Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

H.C. Wainwright initiated coverage on Omeros (OMER) with a Buy rating and a $9 price target, citing the significant long-term potential driven by its rare disease pipeline, particularly Narsoplimab, which has a potential FDA decision on September 25 for TA-TMA with a commercial opportunity between $500 million and $1 billion. While Omeros is refocusing its pipeline and balance sheet to support the Narsoplimab launch, including repurchasing $80 million of convertible notes, the analyst views this as a constructive effort to improve the company's financial position despite the negative market reaction, projecting FY25 EPS of $(1.50) loss, and FY26 EPS of $(1.14) loss.

Analysis

H.C. Wainwright analyst Brandon Folkes has initiated coverage on Omeros Corporation (OMER) with a Buy rating and a $9 price target, highlighting the company's significant long-term value potential stemming from its expansive rare disease pipeline. A pivotal catalyst for Omeros is the upcoming FDA decision on September 25 for its lead asset, Narsoplimab, a MASP-2 inhibitor for treating TA-TMA, a severe complication of stem cell transplants. Approval of Narsoplimab, which has shown promise in improving patient outcomes, could unlock a commercial opportunity estimated between $500 million and $1 billion, potentially validating Omeros's broader pipeline and funding further development of assets like Zaltenibart (OMS906) and OMS1029. In a strategic move, Omeros is temporarily pausing or scaling back certain initiatives to prioritize a successful Narsoplimab launch and focus on assets with clearer commercialization pathways, a decision viewed positively by the analyst. Despite a recent 38% drop in Omeros shares on May 12, 2025, following the disclosure of an $80 million repurchase of its 2026 convertible notes, the analyst considers this a constructive step to strengthen the company's balance sheet and improve its financial outlook ahead of the key FDA decision. The analyst projects an FY25 EPS loss of $(1.50) and an FY26 EPS loss of $(1.14), with Omeros shares currently trading at $3.91, up 3.58% at the time of publication. The overall sentiment surrounding this news is strongly positive, particularly for OMER.

Key Decisions for Investors

• Investors should closely monitor the upcoming FDA decision for Narsoplimab on September 25, as this represents a major inflection point for Omeros with significant commercial implications.
• Consider the analyst's Buy rating and $9 price target, which suggests substantial upside potential, while also acknowledging the inherent risks associated with pre-commercial biotech companies and the projected near-term EPS losses.
• Evaluate Omeros's strategic refocusing of its pipeline and balance sheet strengthening measures, such as the convertible note repurchase, as potentially positive long-term developments despite recent share price volatility.